Oguz Ayten, Tuzun Dilek, Sahin Murat, Bulbul Nese, Celik Ahmet, Guvenc Numan, Inanc Elif, Gul Kamile
Department of Endocrinology and Metabolism, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
Department of Biochemistry, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
Arch Endocrinol Metab. 2015 Dec;59(6):482-6. doi: 10.1590/2359-3997000000096. Epub 2015 Aug 28.
Our aim was to investigate the thyroid function tests and thyroid volume differences among males with isolated hypogonadotropic hypogonadism (IHH) who take androgen replacement treatment (ART).
Forty-four male with IHH with a mean age 33.2 (18-54), diagnosed in Endocrinology and Metabolism Department between September 2013 and September 2014 and 40 healthy male control with a mean age 27.77 (18-55) were involved to study. Patient group was divided to testosterone-treated patients (n = 19) and human chorionic gonadotropine (hCG)-treated patients (n = 25). Patient group was compared in terms of total testosterone, thyroid function tests [thyroid stimulating hormone (TSH), free thyroxine (fT4)] and thyroid volume, before and 6 months after treatment. Patient group was compared with control group as well.
When we compared the patient group with the control group, there was no significant difference for age, Body mass index, TSH, fT4 and thyroid volume between two groups before treatment. There was no difference in terms of TSH, but fT4, testosterone levels and thyroid volume were significantly higher after treatment, when the patient group was compared before and after treatment (p < 0.05). When we compared testosterone-treated patients and hCG-treated patients; thyroid volume was higher among hCG-treated patients (p = 0.001) but there was no difference for thyroid volume before and after testosterone treatment (p > 0.05). There was no statistically significant correlation between testosterone levels with TSH, fT4 and thyroid volume (r = 0.09, p = 0.32; r = 0.14, p = 0.11; r = 0.15, p = 0.09, respectively).
Our study showed that ART increases the thyroid volume especially in hCG-treated patients. Therefore, we suggest that thyroid volume changes should be followed up in hCG-treated patients.
我们的目的是研究接受雄激素替代治疗（ART）的孤立性促性腺激素缺乏性性腺功能减退（IHH）男性患者的甲状腺功能测试及甲状腺体积差异。
纳入2013年9月至2014年9月在内分泌与代谢科诊断的44例平均年龄33.2岁（18 - 54岁）的IHH男性患者以及40例平均年龄27.77岁（18 - 55岁）的健康男性对照进行研究。患者组分为睾酮治疗组（n = 19）和人绒毛膜促性腺激素（hCG）治疗组（n = 25）。比较患者组治疗前及治疗6个月后的总睾酮、甲状腺功能测试[促甲状腺激素（TSH）、游离甲状腺素（fT4）]和甲状腺体积。患者组也与对照组进行比较。
当我们将患者组与对照组进行比较时，治疗前两组在年龄、体重指数、TSH、fT4和甲状腺体积方面无显著差异。当比较患者组治疗前后时，TSH无差异，但fT4、睾酮水平和甲状腺体积在治疗后显著升高（p < 0.05）。当我们比较睾酮治疗组患者和hCG治疗组患者时；hCG治疗组患者的甲状腺体积更高（p = 0.001），但睾酮治疗前后甲状腺体积无差异（p > 0.05）。睾酮水平与TSH、fT4和甲状腺体积之间无统计学显著相关性（r分别为0.09，p = 0.32；r = 0.14，p = 0.11；r = 0.15，p = 0.09）。
我们的研究表明ART会增加甲状腺体积特别是在hCG治疗的患者中。因此，我们建议对hCG治疗的患者随访甲状腺体积变化。
Zotero 插件